Literature DB >> 2726764

Chemical synthesis of echistatin, a potent inhibitor of platelet aggregation from Echis carinatus: synthesis and biological activity of selected analogs.

V M Garsky1, P K Lumma, R M Freidinger, S M Pitzenberger, W C Randall, D F Veber, R J Gould, P A Friedman.   

Abstract

Echistatin, a polypeptide from the venom of the saw-scaled viper, Echis carinatus, containing 49 amino acids and 4 cystine bridges was synthesized by solid-phase methodology in 4% yield. In the final step, air oxidation of the octahydroderivative was found to be optimal at pH 8. The synthetic product was shown to be physically and biologically indistinguishable from native material. It inhibits fibrinogen-dependent platelet aggregation stimulated by ADP with IC50 = 3.3 x 10(-8) M and also prevents aggregation initiated by thrombin, epinephrine, collagen, or platelet-activating factor. Reduction of purified synthetic echistatin to octahydroechistatin with dithiothreitol followed by air oxidation regenerated homogeneous echistatin in quantitative yield. This highly specific refolding strongly suggests that the linear sequence of octahydroechistatin contains all of the information that is required for the proper folding of the peptide. The sequence Arg24-Gly-Asp of echistatin occurs also in adhesive glycoproteins that bind to the platelet fibrinogen receptor--a heterodimeric complex composed of glycoproteins IIb and IIIa. In an effort to evaluate the role of this putative binding site we have synthesized analogs of echistatin with substitution of Arg-24. Replacement with ornithine-24 (Orn-24) resulted in an analog having a platelet aggregation inhibitory activity with IC50 = 1.05 x 10(-7) M. Substitution with Ala-24 gave IC50 = 6.1 x 10(-7) M. The inhibitory activity of the corresponding short sequence analogs Arg-Gly-Asp-Phe (IC50 = 6 x 10(-6) M), Orn-Gly-Asp-Phe (IC50 = 1.3 x 10(-4) M), and Ala-Gly-Asp-Phe (IC50 = 5.0 x 10(-4) M) was also determined. These results suggest that arginine plays a more important role in the binding of the tetrapeptide than in that of echistatin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2726764      PMCID: PMC287380          DOI: 10.1073/pnas.86.11.4022

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

Review 1.  New perspectives in cell adhesion: RGD and integrins.

Authors:  E Ruoslahti; M D Pierschbacher
Journal:  Science       Date:  1987-10-23       Impact factor: 47.728

2.  Lipolytic activity of Met-Arg-His-Phe-Arg-Trp-Gly, a synthetic analog of the ACTH (4-10) core sequence.

Authors:  M W Draper; R B Merrifield; M A Rizack
Journal:  J Med Chem       Date:  1973-12       Impact factor: 7.446

3.  Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain.

Authors:  M Kloczewiak; S Timmons; T J Lukas; J Hawiger
Journal:  Biochemistry       Date:  1984-04-10       Impact factor: 3.162

4.  Quantitative monitoring of solid-phase peptide synthesis by the ninhydrin reaction.

Authors:  V K Sarin; S B Kent; J P Tam; R B Merrifield
Journal:  Anal Biochem       Date:  1981-10       Impact factor: 3.365

5.  Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets.

Authors:  E F Plow; M D Pierschbacher; E Ruoslahti; G Marguerie; M H Ginsberg
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

6.  The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets.

Authors:  E F Plow; M D Pierschbacher; E Ruoslahti; G A Marguerie; M H Ginsberg
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

7.  The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets.

Authors:  T K Gartner; J S Bennett
Journal:  J Biol Chem       Date:  1985-10-05       Impact factor: 5.157

8.  A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.

Authors:  B S Coller
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

9.  Trigramin: primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human platelets.

Authors:  T F Huang; J C Holt; E P Kirby; S Niewiarowski
Journal:  Biochemistry       Date:  1989-01-24       Impact factor: 3.162

10.  Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model.

Authors:  B S Coller; J D Folts; L E Scudder; S R Smith
Journal:  Blood       Date:  1986-09       Impact factor: 22.113

View more
  13 in total

Review 1.  The current role of platelet-active drugs in ischaemic heart disease.

Authors:  D M Kerins; G A FitzGerald
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

2.  An echistatin C-terminal peptide activates GPIIbIIIa binding to fibrinogen, fibronectin, vitronectin and collagen type I and type IV.

Authors:  P S Wright; V Saudek; T J Owen; S L Harbeson; A J Bitonti
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

3.  Immunocytochemical localization of platelets in baboon hepatic sinusoids using monoclonal mouse anti-human platelet glycoprotein IIIa following induction of thrombocytopenia.

Authors:  J D Frank; R J Gould; L W Schaffer; J T Davidson; R E Gibson; D H Patrick; S L Vonderfecht; M E Cartwright
Journal:  Histochemistry       Date:  1992-05

4.  Chemical synthesis and structural characterization of the RGD-protein decorsin: a potent inhibitor of platelet aggregation.

Authors:  P Polverino de Laureto; E Scaramella; V De Filippis; O Marin; M G Doni; A Fontana
Journal:  Protein Sci       Date:  1998-02       Impact factor: 6.725

5.  Echistatin disulfide bridges: selective reduction and linkage assignment.

Authors:  W R Gray
Journal:  Protein Sci       Date:  1993-10       Impact factor: 6.725

6.  Three-dimensional structure of echistatin and dynamics of the active site.

Authors:  Y Chen; A K Suri; D Kominos; G Sanyal; A M Naylor; S M Pitzenberger; V M Garsky; R M Levy; J Baum
Journal:  J Biomol NMR       Date:  1994-05       Impact factor: 2.835

7.  Assignment of all four disulfide bridges in echistatin.

Authors:  M Bauer; Y Sun; C Degenhardt; B Kozikowski
Journal:  J Protein Chem       Date:  1993-12

8.  Quantitative detection of platelet GPIIb-IIIa receptor antagonist activity using a flow cytometric method.

Authors:  L J Green; P Marder; S L Um; J A Jakubowski; J B Lawrence
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

9.  Echistatin prevents posterior capsule opacification in diabetic rabbit model via integrin linked kinase signaling pathway.

Authors:  Fengbin Lin; Yingying Chen; Hao Liang; Shaojian Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

10.  Echistatin is a potent inhibitor of bone resorption in culture.

Authors:  M Sato; M K Sardana; W A Grasser; V M Garsky; J M Murray; R J Gould
Journal:  J Cell Biol       Date:  1990-10       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.